Ameriflex Group Inc. Invests $550,000 in Johnson & Johnson (NYSE:JNJ)

Ameriflex Group Inc. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 3,616 shares of the company's stock, valued at approximately $550,000.

A number of other institutional investors also recently modified their holdings of JNJ. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson during the 4th quarter worth $29,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson during the 4th quarter worth $32,000. Conquis Financial LLC bought a new stake in Johnson & Johnson during the 4th quarter worth $33,000. Finally, Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson during the 4th quarter worth $36,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.2%

Shares of NYSE JNJ traded up $0.31 during midday trading on Tuesday, reaching $153.25. The company had a trading volume of 6,979,932 shares, compared to its average volume of 7,961,247. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm's fifty day moving average price is $155.05 and its 200-day moving average price is $153.65. The stock has a market cap of $368.73 billion, a PE ratio of 23.05, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.39%. Johnson & Johnson's dividend payout ratio is 57.84%.

Analyst Ratings Changes

A number of research firms have commented on JNJ. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Raymond James reduced their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Bank of America reduced their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Morgan Stanley boosted their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.